| Abiraterone Acetate | Janssen Pharma | ||
| 250 mg; Tablet, Oral |
More Than $1000 mn
|
||
|
More Than 5
|
More Than 5
|
||
|
More Than 5
|
None | ||
|
More Than 5
|
More Than 5
|
||
| Metastatic castration-resistant prostate cancer (mCRPC). | |||
|
Yes
| |||
| Zytiga | Patent 1 | Patent 2 |
|---|---|---|
| ******* | ****** ******* (*** ** **) | ******** ** **** *** |
| ****** | ****** ******* (*** ** **) | ******* |
| ****** | ****** ******* (******* ***** *** ** **) | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******* | *** \ ** | *** **, **** | *** ** ** | **** | ****** **** ******** |
| ****** | *** \ *** | *** **, **** | *** ** ** | ******** | ******** ** *** **, **** |
| ****** | *** \ *** | *** **, **** | ******* | ******** | ******** ** *** **, **** |
| Abiraterone Acetate | Janssen Pharma | ||
| 500mg; Tablet, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
|
More Than 5
|
More Than 5
|
||
| Metastatic castration-resistant prostate cancer (mCRPC) | |||
|
Yes
| |||
| Zytiga | Patent 1 | Patent 2 |
|---|---|---|
| **** | ****** ******* (*** ** **) | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| **** | *** \ ** | *** **, **** | *** ** ** | **** | ******** ** *** **** |
Download ParaIV Report